Kieran Rooney

Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

Pharmaceutical Profiles Ltd. develops drugs for pharmaceutical and biotech companies. The company studies how drugs are absorbed and processed in the human body. It utilizes gamma camera imaging products in its studies. It also provides complete scientific, regulatory and medical support for its client's clinical development programs. Pharmaceutical Profiles was founded in 1990 and is headquartered in Nottingham, UK.

Pharsight's products and services help drugmakers build and shape their pipelines and decrease time and money spent on development. Using computer simulation, statistics, and data analysis along with pharmacology, disease and drug modeling, genetics, and databases of biologic information, Pharsight helps clients determine drug-development targets.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.